MCID: ADN027
MIFTS: 61

Adenomyosis

Categories: Muscle diseases, Rare diseases, Reproductive diseases

Aliases & Classifications for Adenomyosis

MalaCards integrated aliases for Adenomyosis:

Name: Adenomyosis 57 12 76 53 44 15
Endometriosis of Uterus 12 15 73
Endometriosis of Myometrium 12
Endometriosis, Myometrium 12
Endometriosis Interna 12
Uterine Adenomyosis 12

Characteristics:

OMIM:

57
Inheritance:
autosomal vs. x-linked dominant


Classifications:



External Ids:

OMIM 57 600458
Disease Ontology 12 DOID:288
ICD10 33 N80.0
ICD9CM 35 617.0
MeSH 44 D062788
NCIt 50 C6996
SNOMED-CT 68 76376003
MedGen 42 C0341858
UMLS 73 C0341858

Summaries for Adenomyosis

NIH Rare Diseases : 53 Adenomyosis is a condition that affects the uterus. In women with adenomyosis, the endometrial tissue (which typically lines the uterus) moves into the outer, muscular walls of the uterus. Some women may have no signs or symptoms of the condition. When present, features of the condition include heavy menstrual bleeding, painful menstrual periods, and pelvic pain during intercourse. Some women may also develop an adenomyoma, which is a mass or growth within the uterus. The underlying cause of the condition is currently unknown. In general, treatment is based on the signs and symptoms present in each person. Forms of birth control that contain progesterone (such as birth control pills or an IUD) may decrease heavy bleeding while certain medications can be used to manage pain. In severe cases, a hysterectomy may be recommended.

MalaCards based summary : Adenomyosis, also known as endometriosis of uterus, is related to uterine anomalies and endometriosis. An important gene associated with Adenomyosis is OXTR (Oxytocin Receptor), and among its related pathways/superpathways are GPCR Pathway and Nanog in Mammalian ESC Pluripotency. The drugs Ketorolac and Ibuprofen have been mentioned in the context of this disorder. Affiliated tissues include uterus, pituitary and endothelial, and related phenotypes are abnormal bleeding and dysmenorrhea

Disease Ontology : 12 A uterine disease that is characterized by the presence of endometrial tissue grows outside of the endometrium, such as into the myometrium.

OMIM : 57 Adenomyosis is characterized by the presence of endometrial glands and stroma within the myometrium. Abnormal uterine bleeding and dysmenorrhea are the most characteristic symptoms, occurring in approximately 65% of cases (Arnold et al., 1995). (600458)

Wikipedia : 76 Adenomyosis is a gynecologic medical condition characterized by the abnormal presence of endometrial... more...

Related Diseases for Adenomyosis

Diseases related to Adenomyosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 216)
# Related Disease Score Top Affiliating Genes
1 uterine anomalies 31.5 CDH1 CYP19A1 ESR1 PGR VEGFA
2 endometriosis 30.5 CYP19A1 ESR1 GNRH1 HOXA10 PGR PTGS2
3 endometrial adenocarcinoma 30.4 ESR1 HOXA10 PGR VEGFA
4 myoma 30.3 CYP19A1 ESR1 GNRH1 HOXA10 PGR
5 leiomyoma 30.2 CYP19A1 ESR1 GNRH1 MME PGR
6 adenosarcoma 30.2 ESR1 MME PGR
7 endometrial stromal sarcoma 30.0 CYP19A1 ESR1 MME PGR
8 endometriosis of ovary 29.9 CYP19A1 ESR1 HOXA10 PGR
9 leiomyomatosis 29.8 ESR1 GNRH1 PGR
10 intravenous leiomyomatosis 29.8 ESR1 MME
11 cystitis 29.8 NGF PTGS2 TRPV1
12 breast fibroadenoma 29.5 CYP19A1 ESR1 MME PGR
13 endometrial cancer 28.9 CDH1 CYP19A1 ESR1 GNRH1 HOXA10 MME
14 breast cancer 28.7 CDH1 CYP19A1 ESR1 GNRH1 MMP2 MMP9
15 adenocarcinoma 10.6
16 infertility 10.4
17 light chain deposition disease 10.3 MMP2 MMP9
18 female reproductive endometrioid cancer 10.3 ESR1 PGR
19 synchronous bilateral breast carcinoma 10.3 ESR1 PGR
20 adamantinous craniopharyngioma 10.3 MMP9 VEGFA
21 vestibular gland benign neoplasm 10.3 ESR1 PGR
22 bartholin's gland adenoma 10.3 ESR1 PGR
23 fungal keratitis 10.3 MMP9 TIMP2
24 vulvar syringoma 10.3 ESR1 PGR
25 extracranial arteriovenous malformation 10.3 MMP2 MMP9
26 glassy cell carcinoma of the cervix 10.3 ESR1 PGR
27 tuberculum sellae meningioma 10.3 PGR PRL
28 lung leiomyoma 10.3 ESR1 PGR
29 focal myositis 10.3 MMP2 MMP9
30 vulvar benign neoplasm 10.3 ESR1 PGR
31 trigonitis 10.3 ESR1 PGR
32 balanitis xerotica obliterans 10.3 PTGS2 VEGFA
33 vulvar leiomyoma 10.3 ESR1 PGR
34 villous adenocarcinoma 10.3 MMP2 MMP9
35 spastic entropion 10.3 MMP2 MMP9
36 extrapelvic endometriosis 10.3
37 lentigo maligna melanoma 10.3 MMP2 MMP9
38 predominantly cortical thymoma 10.3 ESR1 PGR
39 adenomyoma 10.3
40 breast medullary carcinoma 10.3 ESR1 PGR
41 angiokeratoma circumscriptum 10.3 MMP9 VEGFA
42 breast scirrhous carcinoma 10.3 ESR1 PGR
43 bartholin's gland benign neoplasm 10.3 ESR1 PGR
44 oncocytic breast carcinoma 10.2 ESR1 PGR
45 acute transverse myelitis 10.2 MMP2 MMP9
46 intracystic papillary adenoma 10.2 PGR PRL
47 senile ectropion 10.2 MMP2 MMP9
48 progesterone resistance 10.2 ESR1 PGR
49 ischemic colitis 10.2 MMP2 MMP9 VEGFA
50 gingival hypertrophy 10.2 MMP9 TIMP2

Graphical network of the top 20 diseases related to Adenomyosis:



Diseases related to Adenomyosis

Symptoms & Phenotypes for Adenomyosis

Symptoms via clinical synopsis from OMIM:

57
Lab:
dysmenorrhea
endometrial glands and stroma within the myometrium
abnormal uterine bleeding

G U:
adenomyosis


Clinical features from OMIM:

600458

Human phenotypes related to Adenomyosis:

32
# Description HPO Frequency HPO Source Accession
1 abnormal bleeding 32 HP:0001892
2 dysmenorrhea 32 HP:0100607
3 abnormality of the genitourinary system 32 HP:0000119

MGI Mouse Phenotypes related to Adenomyosis:

46 (show all 18)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.36 CDH1 CYP19A1 ESR1 GNRH1 MME MMP2
2 behavior/neurological MP:0005386 10.32 CYP19A1 ESR1 MMP9 NGF OXTR PGR
3 cardiovascular system MP:0005385 10.31 CDH1 CYP19A1 ESR1 MMP2 MMP9 NGF
4 growth/size/body region MP:0005378 10.31 CDH1 CYP19A1 ESR1 GNRH1 HOXA10 MMP2
5 immune system MP:0005387 10.31 CDH1 CYP19A1 ESR1 GNRH1 MME MMP2
6 integument MP:0010771 10.29 CDH1 CYP19A1 ESR1 GNRH1 MME MMP9
7 endocrine/exocrine gland MP:0005379 10.25 CDH1 CYP19A1 ESR1 GNRH1 HOXA10 OXTR
8 hematopoietic system MP:0005397 10.18 CYP19A1 ESR1 GNRH1 MMP2 MMP9 PGR
9 nervous system MP:0003631 10.18 CYP19A1 ESR1 GNRH1 HOXA10 MMP2 MMP9
10 digestive/alimentary MP:0005381 10.16 CDH1 CYP19A1 ESR1 GNRH1 HOXA10 MMP9
11 neoplasm MP:0002006 10.1 CDH1 ESR1 GNRH1 MMP2 MMP9 PGR
12 muscle MP:0005369 10.09 CYP19A1 ESR1 MMP2 MMP9 NGF OXTR
13 liver/biliary system MP:0005370 10.06 CYP19A1 ESR1 GNRH1 MME PRL PTGS2
14 normal MP:0002873 10 CDH1 CYP19A1 ESR1 GNRH1 MMP2 NGF
15 no phenotypic analysis MP:0003012 9.92 CDH1 ESR1 NGF OXTR PGR PTGS2
16 renal/urinary system MP:0005367 9.7 CYP19A1 ESR1 GNRH1 MMP9 PTGS2 TRPV1
17 reproductive system MP:0005389 9.7 CDH1 CYP19A1 ESR1 GNRH1 HOXA10 MMP9
18 skeleton MP:0005390 9.28 CYP19A1 ESR1 GNRH1 HOXA10 MMP2 MMP9

Drugs & Therapeutics for Adenomyosis

Drugs for Adenomyosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 86)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ketorolac Approved Phase 4 66635-83-4, 74103-06-3 3826
2
Ibuprofen Approved Phase 4 15687-27-1 3672
3
Acetaminophen Approved Phase 4 103-90-2 1983
4
Dienogest Approved Phase 4 65928-58-7
5
Nandrolone phenpropionate Approved, Illicit, Investigational Phase 4 62-90-8 229455
6
Nandrolone decanoate Approved, Illicit Phase 4 360-70-3 9677
7
Nandrolone Experimental, Investigational Phase 4 434-22-0 9904
8 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Not Applicable
9 Contraceptives, Oral Phase 4,Phase 2,Phase 3,Early Phase 1,Not Applicable
10 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable
11 Hormones Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable
12 Contraceptive Agents Phase 4,Phase 2,Phase 3,Early Phase 1,Not Applicable
13 Contraceptives, Oral, Combined Phase 4,Phase 2,Early Phase 1,Not Applicable
14 Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable
15 Anti-Inflammatory Agents, Non-Steroidal Phase 4
16 Analgesics, Non-Narcotic Phase 4
17 Antirheumatic Agents Phase 4
18 Anti-Inflammatory Agents Phase 4,Not Applicable
19 Analgesics Phase 4,Phase 3
20 Cyclooxygenase Inhibitors Phase 4
21 Antipyretics Phase 4
22 Antineoplastic Agents, Hormonal Phase 4,Phase 2,Phase 3,Not Applicable
23 Contraceptive Agents, Male Phase 4
24 Androgens Phase 4
25 Anabolic Agents Phase 4
26
Letrozole Approved, Investigational Phase 2, Phase 3 112809-51-5 3902
27
Goserelin Approved Phase 2, Phase 3 65807-02-5 47725 5311128
28
Progesterone Approved, Vet_approved Phase 2, Phase 3 57-83-0 5994
29
Mifepristone Approved, Investigational Phase 2, Phase 3 84371-65-3 55245
30 Ramosetron Investigational Phase 3 132036-88-5
31
Lactitol Investigational Phase 2, Phase 3 585-86-4 3871
32 Neurotransmitter Agents Phase 3,Phase 1
33 Serotonin Agents Phase 3
34 Serotonin Antagonists Phase 3
35 Gastrointestinal Agents Phase 3,Not Applicable
36 Autonomic Agents Phase 3,Not Applicable
37 Antiemetics Phase 3,Not Applicable
38 Estrogens Phase 2, Phase 3,Early Phase 1,Not Applicable
39 Estrogen Antagonists Phase 2, Phase 3
40 Aromatase Inhibitors Phase 2, Phase 3
41 Estrogen Receptor Antagonists Phase 2, Phase 3
42 Steroid Synthesis Inhibitors Phase 2, Phase 3
43 Contraceptives, Postcoital Phase 2, Phase 3
44 Luteolytic Agents Phase 2, Phase 3
45 Micronutrients Phase 3
46 Trace Elements Phase 3
47
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
48
Levonorgestrel Approved, Investigational Phase 2,Early Phase 1,Not Applicable 17489-40-6, 797-63-7 13109
49
Lidocaine Approved, Vet_approved Phase 2 137-58-6 3676
50
Ropivacaine Approved Phase 2 84057-95-4 175805 71273

Interventional clinical trials:

(show top 50) (show all 63)
# Name Status NCT ID Phase Drugs
1 Effectiveness of IV Acetaminophen and IV Ibuprofen in Reducing Post Procedural Pain in the UFE Procedure Completed NCT02227316 Phase 4 IV Ibuprofen;IV Acetaminophen;Intravenous placebo/Intravenous placebo
2 Role of Dienogest in the Treatment of Patient With Symptomatic Adenomyosis Not yet recruiting NCT03654144 Phase 4 Dienogest;Combined Oral Contraceptive
3 Effect of Ulipristal Acetate on Bleeding Patterns and Dysmenorrhea in Women With Adenomyosis Withdrawn NCT03325868 Phase 4 Ulipristal Acetate
4 Single Incision Laparoscopic Surgery (SILS) Versus Conventional Laparoscopic Hysterectomy Unknown status NCT01483417 Phase 3
5 The Use of Doppler to Diagnose Myometrial Masses Unknown status NCT01833871 Phase 2, Phase 3
6 Single-port Access Laparoscopic-assisted Vaginal Hysterectomy Unknown status NCT01048931 Phase 3
7 Long Term Prevention of Nausea and Vomiting in Gynecologic Laparoscopy Unknown status NCT02011659 Phase 3 Ramosetron
8 Aromatase Inhibitors or GnRH-a for Uterine Adenomyosis Completed NCT01218581 Phase 2, Phase 3 received oral letrozole (2.5 mg/day)and goserelin subcutaneosly (3.6 mg/month)
9 Study of Different Pain Scores in Single-Port Access (SPA) Laparoscopic Hysterectomy Versus Conventional Laparoscopic Hysterectomy Completed NCT01064128 Phase 3
10 Evaluation of Therapeutic Effect and Safety of Mifepristone in the Treatment of Adenomyosis Recruiting NCT03520439 Phase 2, Phase 3 Mifepristone;Placebo
11 Efficacy of Trace Elements in the Treatment of Endometriosis: a Pilot Study Active, not recruiting NCT02437175 Phase 3
12 Adenomyosis and Ulipristal Acetate Unknown status NCT02587000 Phase 2 Ulipristal acetate;Placebo
13 LNG-IUS for Treatment of Dysmenorrhea Completed NCT01601366 Phase 2 Combined oral contraceptives
14 Tactile Electrosurgical Ablation in Cases of Dysfunctional Uterine Bleeding Completed NCT02248194 Phase 2
15 Superior Hypogastric Nerve Block for Pain Control Post-UFE Completed NCT02270255 Phase 2 0.75% Ropivacaine;1% Xylocaine
16 Quinagolide Vaginal Ring on Lesion Reduction Assessed by MRI in Women With Endometriosis/Adenomyosis Not yet recruiting NCT03749109 Phase 2 Quinagolide 1080 µg;Placebo
17 Placebo-controlled Proof of Concept Study of Epelsiban in Women With Adenomyosis Withdrawn NCT02794467 Phase 2 Epelsiban;Placebo
18 Vaginal Bromocriptine for Treatment of Adenomyosis Completed NCT01821001 Phase 1 Vaginal Bromocriptine
19 Levonorgestrel-releasing Intrauterine System Versus a Low-dose Combined Oral Contraceptive for Management of Adenomyosis Uteri Unknown status NCT03037944 Early Phase 1 Yasmin
20 Efficacy of Acupuncture on Chronic Pelvic Pain in Women With Endometriosis or Adenomyosis Unknown status NCT01259180 Not Applicable
21 Evaluation of Endometrial Stromal Cell Apoptosis in Adenomyosis Unknown status NCT00172588
22 Proliferation of Endometrial Stromal Cells in Adenomyosis Unknown status NCT00173212
23 Comparison of Estrogen-progestin Therapy in Continuous Regimen Versus Combination Estrogen-progestin Therapy in Continuous Regimen Plus Levonorgestrel-releasing Intrauterine System (LNG-IUS) Unknown status NCT02556411 Not Applicable LNG-IUS 13,5 mg Levonorgestrel;Levonorgestrel 0,10 mg+ ethinylestradiol 0,02 mg
24 Health-Related QoL Among Women Receiving Hysterectomy in NTUH Unknown status NCT00155870
25 Progestin Treatment for Endometrial Stromal Cells in Adenomyosis Unknown status NCT00155051
26 To Compare to 2-channel and Multiple-channel Single Port Laparoscopic-assisted Vaginal Hysterectomy Unknown status NCT01564602 Not Applicable
27 Ovarian Reserve Modification After Lps Hysterectomy With Bilateral Salpingectomy Unknown status NCT02086344 Not Applicable
28 Effect of Shorten Gonadotropin-releasing Hormone Agonist Therapy on the Outcome of in Vitro Fertilization-Embryo Transfer in Patients With Endometriosis Unknown status NCT03006406 Not Applicable Long term GnRH-a (3.75mg)
29 The Impact of Gynecological Surgery on Ovarian Function in Women of Reproductive Age: Postoperative Changes of Serum Anti-Müllerian Hormone (AMH) Unknown status NCT00928044
30 Long Term Outcomes Following Total Laparoscopic Hysterectomy and Laparoscopic Supracervical Hysterectomy Unknown status NCT01289314 Not Applicable
31 Histopathological Diagnosis of Adenomyosis Completed NCT02340533 Not Applicable
32 Norwegian Adenomyosis Study I Completed NCT02201719
33 Levonorgestrel-releasing Intrauterine System for the Treatment of Symptomatic Adenomyosis Completed NCT03027648 Not Applicable
34 Levonorgestrel Intrauterine System and Adenomyosis Completed NCT03104309 Not Applicable
35 Comparison of the Operation and Medical Treatment of Endometriosis and Adenomyosis Completed NCT03778359 Leuprorelin;Dienogest;Progestins
36 New Inflammation Markers for Distinguishing Uterine Adenomyosis and Leiomyoma Completed NCT02997787
37 What Are we Missing? Diagnosing Uterine Adenomyosis Using Ultrasound Elastography Completed NCT01992718 Early Phase 1
38 Study of Diphereline 3.75 mg Treatment In Women Suffering From Internal Genital Endometriosis Completed NCT03586063
39 Use of Dexamethasone in Uterine Artery Embolization Completed NCT02056717 Not Applicable Dexamethasone;Normal saline
40 Uterine Artery Embolization for Symptomatic Fibroids Completed NCT00354471
41 Does 3D Laparoscopy Improve Vaginal Cuff Suture Time? Completed NCT02192606 Not Applicable
42 Use of the Enseal Intrument for Laparoscopic Supracervical Hysterectomy Completed NCT01806012 Not Applicable
43 AMH Levels Change During Treatment With GnRh Agonist Completed NCT02086279 Not Applicable GnRH analogue
44 Magnetic Resonance Imaging (MRI) Hysterosalpingography Versus Radiographic Hysterosalpingography in Female Infertility Completed NCT02108665 Not Applicable
45 Surgical Success After Laparoscopic vs Abdominal Hysterectomy Completed NCT01793584 Not Applicable
46 Electronic Catheter Stethoscope Completed NCT01463462
47 Effect of Salpingectomy During Conservative Hysterectomy Completed NCT01628432 Not Applicable
48 Sonohysterography , 3D Ultrasonography and Hysteroscopy in Assessment of Uterine Factor in Cases of Female Infertility Completed NCT02399501 Not Applicable
49 The Association Between Adenomyosis/Uterine Myoma and Lower Urinary Tract Symptoms Recruiting NCT02495311
50 A Multi-omics Study of Adenomyosis Recruiting NCT03742843

Search NIH Clinical Center for Adenomyosis

Cochrane evidence based reviews: adenomyosis

Genetic Tests for Adenomyosis

Anatomical Context for Adenomyosis

MalaCards organs/tissues related to Adenomyosis:

41
Uterus, Pituitary, Endothelial, Breast, Bone, Lung, Ovary

Publications for Adenomyosis

Articles related to Adenomyosis:

(show top 50) (show all 1051)
# Title Authors Year
1
Endometriosis and adenomyosis are associated with increased risk of preterm delivery and a small-for-gestational-age child: a systematic review and meta-analysis. ( 29753309 )
2018
2
Clinical Usefulness of the Microbubble Contrast Agent SonoVue in Enhancing the Effects of High-Intensity Focused Ultrasound for the Treatment of Adenomyosis. ( 29689636 )
2018
3
Fertility-Sparing Treatment of Adenomyosis in Patients With Infertility: A Systematic Review of Current Options. ( 29402199 )
2018
4
Adenomyosis and urinary system symptoms. ( 29655132 )
2018
5
ILK-induced epithelial-mesenchymal transition promotes the invasive phenotype in adenomyosis. ( 29409901 )
2018
6
The Investigation and Management of Adenomyosis in Women Who Wish to Improve or Preserve Fertility. ( 29736395 )
2018
7
Operation, hormone therapy and recovery of the patients with severe forms of adenomyosis. ( 29447009 )
2018
8
Reproductive Outcomes after Fertility-Sparing Surgery for Focal and Diffuse Adenomyosis: a Systematic Review. ( 29305234 )
2018
9
Is it time for a paradigm shift in drug research and development in endometriosis/adenomyosis? ( 29893860 )
2018
10
The Effect of Adenomyosis in Myometrial Invasion and Overall Survival in Endometrial Cancer. ( 29040186 )
2018
11
Drug Development in Endometriosis and Adenomyosis: It Takes More Than Just Good Science. ( 29962279 )
2018
12
The Risk of Preterm Births Among Pregnant Women With Adenomyosis. ( 29363150 )
2018
13
Effects of pelvic endometriosis and adenomyosis on ciliary beat frequency and muscular contractions in the human fallopian tube. ( 29753325 )
2018
14
Adenomyosis and Endometrial Cancer: Literature Review. ( 29874641 )
2018
15
GnRH agonist improves pregnancy outcome in mice with induced adenomyosis by restoring endometrial receptivity. ( 29922037 )
2018
16
The expression of MA1llerian inhibiting substance/anti-MA1llerian hormone type II receptor in myoma and adenomyosis. ( 29372159 )
2018
17
Re: Pregnancy outcomes in patients with uterine fibroids treated with ultrasound-guided high-intensity focused ultrasound Is the noninvasive nature of HIFU ablation for uterine fibroids and adenomyosis setting patients up for future operative delivery? ( 29405613 )
2018
18
Transvaginal Elastosonography as an Imaging Technique for Diagnosing Adenomyosis. ( 29320956 )
2018
19
The Possible Role of Eukaryotic Translation Initiation Factor 3 Subunit e (eIF3e) in the Epithelial-Mesenchymal Transition in Adenomyosis. ( 29871559 )
2018
20
A sonographic classification and reporting system for diagnosing adenomyosis. ( 29790217 )
2018
21
Combination therapeutic effects of high intensity focused ultrasound and Metformin for the treatment of adenomyosis. ( 29434812 )
2018
22
Evaluation of NovaSure<sup>Ar</sup> global endometrial ablation in symptomatic adenomyosis: A longitudinal study with a 36 month follow-up. ( 29886317 )
2018
23
Anterior Focal Adenomyosis and Bladder Deep Infiltrative: is There a Link? ( 29432902 )
2018
24
Accuracy and Reproducibility of Sonoelastography for the Assessment of Fibroids and Adenomyosis, with Magnetic Resonance Imaging as Reference Standard. ( 29784438 )
2018
25
A clinical audit on the efficacy and safety of uterine artery embolisation for symptomatic adenomyosis: Results in 117 women. ( 29344938 )
2018
26
Endophytic-Type Endometrial Cancer with Adenomyosis Successfully Diagnosed with Hysteroscopic Endometrial Biopsy Using an 8.3-mm Operative Resectoscope: A Case Report. ( 29928209 )
2018
27
Uterine adenomyosis and adenomyoma: the surgical approach. ( 29566853 )
2018
28
Ulipristal Acetate Improves Clinical Symptoms in Women with Adenomyosis and Uterine Myomas. ( 29626678 )
2018
29
Long-term dienogest administration in patients with symptomatic adenomyosis. ( 29845696 )
2018
30
Conservative surgery of diffuse adenomyosis with TOUA: Single surgeon experience of one hundred sixteen cases and report of fertility outcomes. ( 29699636 )
2018
31
Positive associations between upregulated levels of stress-induced phosphoprotein 1 and matrix metalloproteinase-9 in endometriosis/adenomyosis. ( 29304094 )
2018
32
Berberine inhibits growth and inflammatory invasive phenotypes of ectopic stromal cells: Imply the possible treatment of adenomyosis. ( 29752208 )
2018
33
Associations between a single nucleotide polymorphism of stress-induced phosphoprotein 1 and endometriosis/adenomyosis. ( 29673672 )
2018
34
Conservative surgery of uterine adenomyosis via laparoscopic versus laparotomic approach in a single institution. ( 29845687 )
2018
35
Re: A comparison of the cost-utility of ultrasound-guided high-intensity focused ultrasound and hysterectomy for adenomyosis: a retrospective study Is the cost-effectiveness of HIFU for adenomyosis and fibroids feasible? ( 29405542 )
2018
36
Introduction: Uterine adenomyosis, another enigmatic disease of our time. ( 29526476 )
2018
37
Drug therapy for adenomyosis: a prospective, nonrandomized, parallel-controlled study. ( 29552942 )
2018
38
News on Adenomyosis. ( 29554861 )
2018
39
Minimally invasive treatment of adenomyosis. ( 29555380 )
2018
40
Pathogenesis of uterine adenomyosis: invagination or metaplasia? ( 29566849 )
2018
41
Symptoms and classification of uterine adenomyosis, including the place of hysteroscopy in diagnosis. ( 29566850 )
2018
42
Role of transvaginal sonography and magnetic resonance imaging in the diagnosis of uterine adenomyosis. ( 29566851 )
2018
43
Role of medical therapy in the management of uterine adenomyosis. ( 29566852 )
2018
44
Association of Endometriosis and Adenomyosis: Vast Literature but Scant Conclusive Data. ( 29581073 )
2018
45
Combination of microwave endometrial ablation and postoperative dienogest administration is effective for treating symptomatic adenomyosis. ( 29998482 )
2018
46
Menstruation-related disseminated intravascular coagulation in an adenomyosis patient: case report and review of the literature. ( 30044152 )
2018
47
Adenomyosis and IVF/ICSI treatment: clinical considerations and recommendations. ( 30063420 )
2018
48
Current facts constituting an understanding of the nature of adenomyosis. ( 30085434 )
2018
49
Use of Uterine Characteristics to Improve Fertility-Sparing Diagnosis of Adenomyosis. ( 30087549 )
2018
50
Coexistence of adenomyosis, adenocarcinoma, endometrial and myometrial lesions in resected uterine specimens. ( 30101029 )
2018

Variations for Adenomyosis

Expression for Adenomyosis

Search GEO for disease gene expression data for Adenomyosis.

Pathways for Adenomyosis

Pathways related to Adenomyosis according to GeneCards Suite gene sharing:

(show all 26)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.57 ESR1 GNRH1 MMP2 MMP9 NGF PTGS2
2
Show member pathways
13.13 CDH1 ESR1 GNRH1 NGF TIMP2 VEGFA
3
Show member pathways
12.9 ESR1 MMP2 MMP9 PGR VEGFA
4
Show member pathways
12.64 CDH1 ESR1 MMP2 MMP9 VEGFA
5 12.6 CDH1 ESR1 MMP2 MMP9 PTGS2 VEGFA
6
Show member pathways
12.52 GNRH1 MMP2 NGF TRPV1 VEGFA
7 12.15 ESR1 MMP2 MMP9 VEGFA
8 11.98 CDH1 CYP19A1 ESR1 VEGFA
9
Show member pathways
11.94 CDH1 GNRH1 NGF TIMP2
10 11.88 CDH1 MMP2 MMP9
11
Show member pathways
11.82 ESR1 PGR PRL
12 11.81 MMP2 MMP9 PTGS2 VEGFA
13
Show member pathways
11.76 MMP2 MMP9 TIMP2
14 11.66 CDH1 MMP2 MMP9
15 11.53 MMP2 MMP9 TIMP2
16 11.51 MMP2 MMP9 PTGS2 TIMP2
17 11.5 MMP9 PTGS2 VEGFA
18 11.38 ESR1 PTGS2 VEGFA
19 11.32 CDH1 MMP2 MMP9 VEGFA
20 11.24 CDH1 MMP2 MMP9 PTGS2 VEGFA
21 11.16 MME MMP2 MMP9
22
Show member pathways
11.06 MMP2 MMP9 PTGS2 VEGFA
23 11.02 ESR1 MMP2 MMP9
24 10.92 MMP9 TIMP2 VEGFA
25 10.86 MME MMP2 MMP9
26 10.11 CYP19A1 ESR1

GO Terms for Adenomyosis

Cellular components related to Adenomyosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.7 GNRH1 MMP2 MMP9 NGF PRL TIMP2
2 extracellular region GO:0005576 9.56 CDH1 GNRH1 MMP2 MMP9 NGF PRL
3 extracellular matrix GO:0031012 8.92 MMP2 MMP9 TIMP2 VEGFA

Biological processes related to Adenomyosis according to GeneCards Suite gene sharing:

(show all 24)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 9.95 GNRH1 MMP9 NGF PTGS2 VEGFA
2 positive regulation of apoptotic process GO:0043065 9.91 MMP9 NGF PTGS2 TRPV1
3 cytokine-mediated signaling pathway GO:0019221 9.86 MMP2 MMP9 PTGS2 VEGFA
4 female pregnancy GO:0007565 9.75 GNRH1 OXTR PRL
5 response to organic substance GO:0010033 9.74 CDH1 PTGS2 TIMP2
6 memory GO:0007613 9.7 NGF OXTR PTGS2
7 negative regulation of cysteine-type endopeptidase activity involved in apoptotic process GO:0043154 9.69 NGF PTGS2 VEGFA
8 extracellular matrix disassembly GO:0022617 9.67 MMP2 MMP9 TIMP2
9 response to cytokine GO:0034097 9.65 OXTR PTGS2 TIMP2
10 response to peptide hormone GO:0043434 9.63 GNRH1 OXTR TRPV1
11 cellular response to ATP GO:0071318 9.62 PTGS2 TRPV1
12 androgen metabolic process GO:0008209 9.61 CYP19A1 ESR1
13 sensory perception of pain GO:0019233 9.61 MME PTGS2 TRPV1
14 macrophage differentiation GO:0030225 9.6 MMP9 VEGFA
15 mammary gland alveolus development GO:0060749 9.59 ESR1 VEGFA
16 estrous cycle GO:0044849 9.58 GNRH1 OXTR
17 lactation GO:0007595 9.58 OXTR PRL VEGFA
18 response to organic cyclic compound GO:0014070 9.56 GNRH1 OXTR PRL PTGS2
19 response to drug GO:0042493 9.55 CDH1 OXTR PRL PTGS2 TIMP2
20 ovulation cycle GO:0042698 9.54 GNRH1 PRL
21 embryo implantation GO:0007566 9.54 MMP2 MMP9 PTGS2
22 mammary gland development GO:0030879 9.5 CYP19A1 PGR PRL
23 response to estradiol GO:0032355 9.26 ESR1 OXTR PRL PTGS2
24 uterus development GO:0060065 8.8 CYP19A1 ESR1 HOXA10

Molecular functions related to Adenomyosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 metal ion binding GO:0046872 9.65 CDH1 CYP19A1 ESR1 MME MMP2 MMP9
2 identical protein binding GO:0042802 9.63 CDH1 ESR1 MMP9 PGR TRPV1 VEGFA
3 metalloendopeptidase activity GO:0004222 9.43 MME MMP2 MMP9
4 metalloendopeptidase inhibitor activity GO:0008191 9.32 NGF TIMP2
5 zinc ion binding GO:0008270 9.1 ESR1 MME MMP2 MMP9 PGR TIMP2

Sources for Adenomyosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....